keyword
MENU ▼
Read by QxMD icon Read
search

Haploidentical

keyword
https://www.readbyqxmd.com/read/29155367/predicted-indirectly-recognizable-hla-epitopes-are-not-associated-with-clinical-outcomes-after-haploidentical-hematopoietic-stem-cell-transplantation
#1
Ming-Rui Huo, Dan Li, Ying-Jun Chang, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang
Haploidentical stem cell transplantation (haplo-SCT) provides an alternative method to cure patients with malignant and nonmalignant hematologic diseases who lack a human leukocyte antigen (HLA) matched related or unrelated donor. HLA disparity between donor and patient was the main reason causing lots of clinical immune response. The aim of this study was to investigate whether indirect recognition of mismatched HLA could predict the clinical outcomes in haplo-SCT. The probability of indirect recognition was predicted by the Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) model...
November 16, 2017: Human Immunology
https://www.readbyqxmd.com/read/29155317/treosulfan-fludarabine-conditioning-for-hsct-in-children-with-primary-immunodeficiency-uk-experience
#2
Mary A Slatter, Kanchan Rao, Intan Juliana Abd Hamid, Zohreh Nademi, Robert Chiesa, Reem Elfeky, Mark S Pearce, Persis Amrolia, Austen Worth, Terence Flood, Mario Abinun, Sophie Hambleton, Waseem Qasim, Hubert B Gaspar, Andrew J Cant, Andrew R Gennery, Paul Veys
We previously published results of 70 children who received treosulfan with cyclophosphamide (30) or fludarabine (40) before haematopoietic stem cell transplantation (HSCT) for Primary Immunodeficiency (PID). Toxicity was lower and T cell chimerism better in those receiving fludarabine, but numbers were relatively small and follow-up short. We now report outcome of 160 children who received homogeneous conditioning with treosulfan, fludarabine mostly with alemtuzumab (n=124). Median age at transplant was 1...
November 16, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29155271/t-cell-replete-haploidentical-transplantation-in-acute-myeloid-leukemia
#3
Luca Castagna, Raynier Devillier, Norbert Vey, Didier Blaise
In the last decade, the number of haploidentical transplantation is enhanced and this because of the widespread use of T cell replete platforms, developed worldwide. Acute myeloid leukemia is the main indication to perform an allogeneic stem cell transplantation. In this paper, we reviewed the clinical results obtained using T cell replete platforms in different clinical situations such as first or further complete remission, refractory disease, and elderly population. Overall, the toxic profile of T cell replete haploidentical transplantation is similar to transplantation from other donors, with some positive aspects such as a reduced incidence of chronic graft versus host disease...
November 16, 2017: Experimental Hematology
https://www.readbyqxmd.com/read/29147612/low-dose-post-transplant-cyclophosphamide-can-mitigate-gvhd-and-enhance-the-g-csf-atg-induced-gvhd-protective-activity-and-improve-haploidentical-transplant-outcomes
#4
Yu Wang, Ying-Jun Chang, Lu Chen, Lan-Ping Xu, Zhi-Lei Bian, Xiao-Hui Zhang, Chen-Hua Yan, Kai-Yan Liu, Xiao-Jun Huang
Use of high-dose, post-transplant cyclophosphamide (PTCy) results in low rates of graft-versus-host-disease (GVHD) and favorable immune reconstitution, although with higher rates of relapse and somewhat high rates of graft failure. We hypothesized that permissible dose reduction of PTCy might be feasible. The current study attempts to establish a murine model and focus on regulatory T cells (Tregs) to clarify the immunological mechanisms for GVHD prevention by low-dose PTCy. In addition, a prospective, clinical cohort study in haploidentical, T-cell replete transplantation is initiated to support the rational...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/29143887/diagnosis-and-treatment-of-aplastic-anemia
#5
REVIEW
Scott A Peslak, Timothy Olson, Daria V Babushok
Acquired aplastic anemia (AA) is a rare, life-threatening bone marrow failure (BMF) disorder that affects patients of all ages and is caused by lymphocyte destruction of early hematopoietic cells. Diagnosis of AA requires a comprehensive approach with prompt evaluation for inherited and secondary causes of bone marrow aplasia, while providing aggressive supportive care. The choice of frontline therapy is determined by a number of factors including AA severity, age of the patient, donor availability, and access to optimal therapies...
November 16, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29137385/improved-outcome-of-haploidentical-transplantation-in-severe-aplastic-anemia-using-reduced-intensity-fludarabine-based-conditioning
#6
Wu Yamei, Luo Rongmu, Cao Yongbin, Si Yingjian, Li Xiaohong, Zhang Xiaomei, Yan Pei, Du Zhenlan, Wang Haitao, Wang Jing, Wang Bojing, Wu Xiaoxiong, Da Wanming
Significant improvements in hematopoietic stem cell transplantation (HSCT) with haploidentical family donors (HFD) have confirmed its therapeutic role in severe aplastic anemia (SAA) and led to the evolution of treatment algorithms. However, the optimal conditioning regimen for HFD-HSCT remains undefined, especially the dosage of cyclophosphamide (Cy). A total of 77 patients with SAA from two research centers, who received HFD-HSCT with reduced-intensity fludarabine + cyclophosphamide + thymoglobulin ± busulfan conditioning regimen plus third-party cells infusion were included in this study, of which 67 pairs had 4-5 loci mismatched...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29132903/progressive-multifocal-leukoencephalopathy-in-patients-receiving-rituximab-and-cyclophosphamide-after-haplo-identical-t-cell-replete-transplantation-and-review-of-the-literature
#7
REVIEW
R Salem, R Massoud, S S Kanj, M Hamdan, R Salman, A Bazarbachi, J El-Cheikh
John Cunningham virus (JCV) reactivation, occurring mainly in immunocompromised patients, leads to progressive multifocal leukoencephalopathy, an uncommon but lethal disease. JCV reactivation after T-cell replete haploidentical stem cell transplantation, in the pre-cyclophosphamide era, is poorly represented in the literature. We therefore describe two cases of acute myeloid leukemia who developed JCV reactivation after receiving cyclophosphamide and rituximab post haploidentical stem cell transplantation, and review the literature, aiming to a better understanding of the disease course and its risk factors...
November 10, 2017: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29128555/combined-haploidentical-and-umbilical-cord-blood-allogeneic-stem-cell-transplantation-for-high-risk-lymphoma-and-cll
#8
Jingmei Hsu, Andrew Artz, Sebastian A Mayer, Danielle Guarner, Michael R Bishop, Ronit Reich-Slotky, Sonali M Smith, June Greenberg, Justin Kline, Rosanna Ferrante, Adrienne A Phillips, Usama Gergis, Hongtao Liu, Wendy Stock, Melissa Cushing, Tsiporah B Shore, Koen van Besien
Limited studies have reported on outcomes for lymphoid malignancy patients receiving alternative donor allogeneic stem cell transplants. We have previously described combining CD34-selected haploidentical grafts with umbilical cord blood (haplo-cord) to accelerate neutrophil and platelet engraftment. Here, we examine the outcome of patients with lymphoid malignancies undergoing haplo-cord transplantation at the University of Chicago and Weill Cornell Medical College. We analyzed 42 lymphoma and CLL patients who underwent haplo-cord allogeneic stem cell transplantation...
November 8, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29127679/alternative-donor-unrelated-donor-transplants-for-the-%C3%AE-thalassemia-and-sickle-cell-disease
#9
Courtney D Fitzhugh, Allistair Abraham, Matthew M Hsieh
Considerable progress with respect to donor source has been achieved in allogeneic stem cell transplant for patients with hemoglobin disorders, with matched sibling donors in the 1980s, matched unrelated donors and cord blood sources in the 1990s, and haploidentical donors in the 2000s. Many studies have solidified hematopoietic progenitors from matched sibling marrow, cord blood, or mobilized peripheral blood as the best source-with the lowest graft rejection and graft versus host disease (GvHD), and highest disease-free survival rates...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29114918/donor-age-determines-outcome-in-acute-leukemia-patients-over-40-undergoing-haploidentical-hematopoietic-cell-transplantation
#10
Jonathan Canaani, Bipin N Savani, Myriam Labopin, Xiao-Jun Huang, Fabio Ciceri, William Arcese, Yener Koc, Johanna Tischer, Didier Blaise, Zafer Gülbas, Maria Teresa Van Lint, Benedetto Bruno, Mohamad Mohty, Arnon Nagler
Haploidentical hematopoietic cell transplantation (haplo-HCT) is being increasingly used in acute leukemia patients as an alternative transplant modality when matched sibling or matched unrelated donors are unavailable. As several potential haploidentical relative donors are typically available for a given patient, optimizing donor selection to improve clinical outcome is crucial. The impact of donor age and kinship on the outcome of acute leukemia patients is not clearly established in this setting. Using the multinational registry of the acute leukemia working party of the European society for blood and marrow transplantation we retrospective analyzed the clinical outcome of 1270 acute myeloid leukemia and acute lymphoblastic leukemia patients who underwent haplo-HCT between 2005 and 2015...
November 8, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29104089/rag-deficiency-with-alps-features-successfully-treated-with-tcr%C3%AE-%C3%AE-cd19-cell-depleted-haploidentical-stem-cell-transplant
#11
Emma Westermann-Clark, Alice Grossi, Francesca Fioredda, Stefano Giardino, Enrico Cappelli, Paola Terranova, Elena Palmisani, Jocelyn R Farmer, Zsofia Foldvari, Yasuhiro Yamazaki, Maura Faraci, Edoardo Lanino, Luigi D Notarangelo, Carlo Dufour, Isabella Ceccherini, Jolan E Walter, Maurizio Miano
No abstract text is available yet for this article.
November 2, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/29100558/immunohaematological-complications-in-patients-with-sickle-cell-disease-after-haemopoietic-progenitor-cell-transplantation-a-prospective-single-centre-observational-study
#12
Elizabeth S Allen, Kshitij Srivastava, Matthew M Hsieh, Courtney D Fitzhugh, Harvey G Klein, John F Tisdale, Willy A Flegel
BACKGROUND: Haemopoietic progenitor cell (HPC) transplantation can cure sickle cell disease. Non-myeloablative conditioning typically results in donor-derived erythrocytes and stable mixed chimerism of recipient-derived and donor-derived leucocytes. Exposure to donor antigens from the HPC graft and new red cell antibodies induced by transfusion can lead to immunohaematological complications. We assessed the incidence of such complications among HPC transplant recipients with sickle cell disease...
November 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29090489/reconstitution-of-t-and-nk-cells-after-haploidentical-hematopoietic-cell-transplantation-using-%C3%AE-%C3%AE-t-cell-depleted-grafts-and-the-clinical-implication-of-%C3%AE-%C3%AE-t-cells
#13
Meerim Park, Ho Joon Im, Yu-Jin Lee, Nuree Park, Seongsoo Jang, Seog Woon Kwon, Chan-Jeoung Park, Eun Seok Choi, Kyung Nam Koh, Jong Jin Seo
To investigate reconstitution of T and NK cells after αβ T lymphocyte-depleted haploidentical hematopoietic cell transplantation (HHCT) and the clinical implications of γδ T cells, we analyzed 50 pediatric patients who received 55 HHCTs using αβ T cell-depleted grafts. The number of CD3+ T cells and CD8+ T cells recovered rapidly and reached donor levels at days 180 and 60, respectively. Recovery of NK cells was rapid and the median of NK cells at day 14 was comparable to the donor level. At day 14, median percentage of γδ T lymphocytes was 70...
November 1, 2017: Clinical Transplantation
https://www.readbyqxmd.com/read/29084206/myeloablative-conditioning-regimens-with-combined-of-haploidentical-and-cord-blood-transplantation-for-myelodysplastic-syndrome-patients
#14
P Ke, X-B Bao, X-H Hu, J Zhuang, X-J Wu, Y-J Liu, X-F He, D-P Wu, S-L Xue, X Ma
The purpose of this study was to evaluate the strategy of haploidentical (HID) stem cell combined with a small doses of umbilical cord blood (UCB) from a third-party donor transplantation (haplo-cord transplant) for treatment of myelodysplastic syndromes (MDS), by comparing with identical-sibling donor (ISD) transplantation. Eighty-five patients were included between January 2012 and December 2015, with a median 40 years old. Forty-eight patients received haplo-cord transplant and 37 patients received ISD transplant...
October 30, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29084024/haploidentical-stem-cell-transplantation-with-tcr-alpha-beta-and-cd19-depletion-in-a-case-of-unstable-hemoglobin-disease
#15
Karunakumar Kumar, Shobha Badiger, Sharat Damodar, Sunil Bhat
No abstract text is available yet for this article.
October 27, 2017: Transplantation
https://www.readbyqxmd.com/read/29076142/donor-derived-cd19-targeted-t-cell-infusion-induces-minimal-residual-disease-negative-remission-in-relapsed-b-cell-acute-lymphoblastic-leukaemia-with-no-response-to-donor-lymphocyte-infusions-after-haploidentical-haematopoietic-stem-cell-transplantation
#16
Yuhong Chen, Yifei Cheng, Pan Suo, Chenhua Yan, Yu Wang, Yao Chen, Wei Han, Lanping Xu, Xiaohui Zhang, Kaiyan Liu, Lungji Chang, Lei Xiao, Xiaojun Huang
Relapse is a common cause of failure in patients with B-cell acute lymphoblastic leukaemia (B-ALL) after haploidentical haematopoietic stem cell transplantation (haplo-HSCT), and non-responders to donor lymphoblastic infusion after HSCT have a very poor prognosis. Although donor-derived CD19-directed chimeric antigen receptor-modified (CAR) T cells can potentially cure leukaemia, their effectiveness and safety have not been confirmed in relapsed B-ALL cases after haplo-HSCT. Between January 2015 and January 2017, two and four patients each received one and two infusions of CAR T cells from haplo-HSCT donors...
October 26, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/29075259/virus-specific-t-cells-for-the-immunocompromised-patient
#17
REVIEW
Amy Houghtelin, Catherine M Bollard
While progress has been made in the treatment of both hematologic cancers and solid tumors, chemorefractory or relapsed disease often portends a dismal prognosis, and salvage chemotherapy or radiation expose patients to intolerable toxicities and may not be effective. Hematopoietic stem cell transplant offers the promise of cure for many patients, and while mismatched, unrelated or haploidentical donors are increasingly available, the recipients are at higher risk of severe immunosuppression and immune dysregulation due to graft versus host disease...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29070137/-clinical-study-on-treatment-of-juvenile-myelomonocytic-leukemia-with-haploidentical-hematopoietic-stem-cell-transplantation
#18
Li Ding, Heng Zhu, Dong-Mei Han, Zhi-Dong Wang, Xiao-Li Zheng, Lei Dong, Hong-Min Yan, Jing Liu, Ling Zhu, Mei Xue, Zi-Kuan Guo, Heng-Xiang Wang
OBJECTIVE: To analyze the therapeutic efficacy of haploidentical-hematopoietic stem cell transplantation (hi-HSCT) for patients with juvenile myelomonocytic leukemia (JMML). METHODS: The engraftment of hematopoietic stem cells, incidence of graft versus host disease (GVHD), infection, relapse, and survival of 6 JMML patients received hi-HSCT were retrospectively analyzed. RESULTS: Six (6 males) JMML patients received hi-HSCT from haplo-HLA-matched related donors...
October 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29061533/homeostatic-%C3%AE-%C3%AE-t-cell-contents-are-preserved-by-granulocyte-colony-stimulating-factor-priming-and-correlate-with-the-early-recovery-of-%C3%AE-%C3%AE-t-subsets-after-haploidentical-hematopoietic-transplantation
#19
Zhilei Bian, Lan-Ping Xu, Qiang Fu, Mingrui Huo, Long Liu, Xiaosu Zhao, Xiao-Jun Huang, Jiangying Liu
Emerging evidence from graft manipulations and immunotherapeutic treatments has highlighted a favorable effect of γδ T cells in the setting of allogeneic hematopoietic stem cell transplantation (alloHSCT). However, γδ T subsets and their distinct features in the allograft have not been characterized. Additionally, whether homeostatic γδ T-cell fractions are influenced by treatment with granulocyte colony-stimulating factor (G-CSF) remains elusive. We initially compared the phenotypes of γδ T subsets including CD27+, CD27(-), Vδ1+, Vδ2+, Vδ1+CD27+, Vδ1+CD27(-), Vδ2+CD27+, and Vδ2+CD27(-) cells, in the peripheral blood of 20 healthy donors before and after G-CSF mobilization...
October 20, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29055682/grade-ii-acute-graft-versus-host-disease-and-higher-nucleated-cell-graft-dose-improve-progression-free-survival-after-hla-haploidentical-transplant-with-post-transplant-cyclophosphamide
#20
Shannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, Yvette L Kasamon, Margaret M Showel, Javier Bolaños-Meade, Carol Ann Huff, Ivan Borrello, William H Matsui, Robert A Brodsky, Richard F Ambinder, Maria P Bettinotti, Ephraim J Fuchs, Gary L Rosner, Richard J Jones, Leo Luznik
Compared with standard graft-versus-host disease (GVHD) prophylaxis platforms, post-transplantation cyclophosphamide (PTCy) after T cell-replete HLA-haploidentical (haplo) bone marrow transplantation (BMT) reduces the risk of grades III to IV acute (a) and chronic (c) GVHD but maintains similar rates of grade II aGVHD. Given that mild GVHD has been associated with reduced treatment failure in HLA-matched BMT, we evaluated the risk factors for and effects of GVHD on survival in 340 adults with hematologic malignancies who engrafted after nonmyeloablative haplo-BMT with PTCy, mycophenolate mofetil, and tacrolimus...
October 18, 2017: Biology of Blood and Marrow Transplantation
keyword
keyword
6063
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"